BetterLife Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.06
- Today's High:
- $0.062
- Open Price:
- $0.061
- 52W Low:
- $0.032
- 52W High:
- $0.194
- Prev. Close:
- $0.062
- Volume:
- 19700
Company Statistics
- Market Cap.:
- $6.81 million
- Book Value:
- -0.117
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-22808
- Profit Margin:
- 0%
- Return on Assets TTM:
- -404.69%
- Return on Equity TTM:
- -4416.54%
Company Profile
BetterLife Pharma Inc had its IPO on under the ticker symbol BETRF.
The company operates in the Healthcare sector and Biotechnology industry. BetterLife Pharma Inc has a staff strength of 0 employees.
Stock update
Shares of BetterLife Pharma Inc opened at $0.06 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.06 - $0.06, and closed at $0.06.
This is a 0% increase from the previous day's closing price.
A total volume of 19,700 shares were traded at the close of the day’s session.
In the last one week, shares of BetterLife Pharma Inc have slipped by -4.62%.
BetterLife Pharma Inc's Key Ratios
BetterLife Pharma Inc has a market cap of $6.81 million, indicating a price to book ratio of 13.6461 and a price to sales ratio of 0.
In the last 12-months BetterLife Pharma Inc’s revenue was $0 with a gross profit of $-22808 and an EBITDA of $-10690532. The EBITDA ratio measures BetterLife Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BetterLife Pharma Inc’s operating margin was 0% while its return on assets stood at -404.69% with a return of equity of -4416.54%.
In Q0.33333333333333, BetterLife Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
BetterLife Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BetterLife Pharma Inc’s profitability.
BetterLife Pharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.24. Its price to sales ratio in the trailing 12-months stood at 0.
BetterLife Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $74727.00
- Total Liabilities
- $7.15 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
BetterLife Pharma Inc ended 2024 with $74727.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $74727.00 while shareholder equity stood at $-10728221.00.
BetterLife Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $7.15 million in other current liabilities, in common stock, $-112186681.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8307.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
BetterLife Pharma Inc’s total current assets stands at $74727.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $17196.00 compared to accounts payable of $5.44 million and inventory worth $0.
In 2024, BetterLife Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, BetterLife Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.06
- 52-Week High
- $0.194
- 52-Week Low
- $0.032
- Analyst Target Price
- $
BetterLife Pharma Inc stock is currently trading at $0.06 per share. It touched a 52-week high of $0.194 and a 52-week low of $0.194. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.06 and 200-day moving average was $0.08 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 877.2% of the company’s stock are held by insiders while 0.4% are held by institutions.
Frequently Asked Questions About BetterLife Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company’s pipeline products include BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.